Business Context and Reporting Period
This Form 8-K was filed by Akebia Therapeutics, Inc. on August 11, 2023. The filing addresses a notification received from the Nasdaq Stock Market regarding the Company's failure to timely file its Quarterly Report on Form 10-Q for the fiscal quarter ended June 30, 2023.
Key Financial Metrics
This filing is a current report regarding regulatory compliance and does not contain specific financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity figures. The filing text does not provide a clear value for these metrics.
Material Changes and Events
- Nasdaq Non-Compliance: The Company received notice of non-compliance with Nasdaq Listing Rule 5250(c)(1) due to the late filing of the Q2 2023 Form 10-Q.
- Accounting Errors: The delay is attributed to the identification of accounting errors related to the recording and reporting of return reserves for the product Auryxia (ferric citrate). These errors affect financial statements for fiscal years 2020, 2021, 2022, and the quarter ended March 31, 2023.
- Compliance Timeline: The Company has 60 calendar days (until October 10, 2023) to submit a plan to regain compliance. If accepted, Nasdaq may grant an extension of up to 180 days from the original due date (until February 5, 2024) to file the report.
- Trading Status: Common stock (AKBA) continues to trade on the Nasdaq Capital Market pending review of the compliance plan.
Outlook, Risks, and Management Commentary
Management intends to submit a plan to regain compliance prior to October 10, 2023, and file the Quarterly Report as soon as possible. The Company is currently assessing its internal controls over financial reporting to address the identified return reserve errors. The filing includes standard forward-looking statements disclaiming obligations to update future expectations regarding the timing of the plan submission and report filing.
Investor Verification Checklist
- Verify the specific financial impact of the "Return Reserve Errors" on prior fiscal years once the restated reports are filed.
- Monitor the submission of the compliance plan to Nasdaq by the October 10, 2023 deadline.
- Confirm the final filing date of the Q2 2023 Form 10-Q to ensure it meets the extended deadline if granted.
- Review the Company's internal control assessment results regarding the accounting errors.